Imaging Device Tested to Find Lung Segment Borders During Lung Cancer Surgery
Tests a hyperspectral imaging device to locate lung segment borders during lung cancer surgery.
Plain-language title generated from the registry record
Registry title: HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections
Key facts
- Where
- Großhansdorf, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage lung cancer, or with nodules suspected to be cancer, who are having part of a lung removed by surgery.
- Age
- 18 years or older, with no upper age limit.
- Sex
- All sexes can join.
- Disease stage
- Lung cancer stage I/II confirmed by tissue examination, or nodules suspected to be cancer. A segment removal (segmentectomy) must be medically indicated, or weak lung or heart function must prevent removal of a whole anatomical section.
- Earlier treatment
- Not stated. People must not have joined another interventional trial in the last 30 days.
- Biomarker or test result
- Kidney, liver and bilirubin blood tests must be within set limits: serum creatinine up to 1.5 x upper limit of normal or creatinine clearance 50 mL/min or more, total bilirubin up to 1.5 x upper limit of normal, AST/ALT up to 2.5 x upper limit of normal.
Main reasons for not taking part
- Needing a lobectomy or pneumonectomy to remove the tumour completely
- Allergy to indocyanine green or iodine
- Hyperthyroidism
- Current or planned pregnancy, or nursing
- Covid19 / SARS-CoV2 infection at the time of screening
Read by machine on 12 November 2026.
Where in Germany
- LungenClinic GroßhansdorfGroßhansdorf, GermanyContact: David B Ellebrecht, MDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- LungenClinic Grosshansdorf
- Trial code
- NCT05676788
- Record updated
- 9 January 2023
- Original description
The purpose of this study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation.Read full original descriptionShow less
Hyperspectral Imaging for Intersegmental Plane Identification During Sublobar Pulmonary Resections in Lung Cancer Patients
The purpose of this study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation.
Inclusion: Histologically confirmed lung cancer stage I/II or malignancy suspicious nodules; Segmentectomy is oncologically indicated or impaired pulmonary and/or cardiac function prevent anatomical resection; Male or female patients aged ≥ 18 years without upper age limit; Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance (CrCl ≥ 50 mL/min, Cockcroft-Gault formula); Total bilirubin ≤ 1.5 x upper limit of normal (except patients with Gilbert Syndrome (Morbus Meulengracht) in whom total bilirubin < 3.0 mg/dL is allowed); Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase)/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase) ≤ 2.5 x upper limit of normal; Full legal capacity; Written informed consent obtained according to international guidelines and local laws; Ability to understand the nature of the trial and the trial related procedures and to comply with them.
Exclusion: Requirement of a lobectomy or pneumonectomy to achieve complete resection; Participation in any other interventional clinical trial within the last 30 days before the start of this trial; Known or persistent abuse of medication, drugs or alcohol; Allergy to indocyanine green or iodine; Medical condition which poses a high risk to undergo surgery as defined by the investigator; Covid19 / SARS-CoV2-infection at time of screening; Hyperthyroidism; Current or planned pregnancy, nursing period (if defined as requirement of clinical routine treatment); Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed; Person who is in a relationship of dependence/employment with the coordinating investigator or the investigator.